NNVC — NanoViricides Share Price
Last trade - 00:00- $12.96m
- $7.71m
- 24
- 37
- 29
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.04 | ||
| Price to Tang. Book | 1.07 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -77.93% | ||
| Return on Equity | -57.9% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.
Directors
- Anil Diwan CHM (63)
- Meeta Vyas CFO (63)
- Stanley Glick IND (85)
- Makarand Jawadekar IND (70)
- Theodore Rokita IND (51)
- Brian Zucker IND (59)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 1st, 2005
- Public Since
- August 12th, 2004
- No. of Shareholders
- 152
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 11,779,000
- Address
- 1 Controls Drive, SHELTON, 06484
- Web
- http://www.nanoviricides.com/
- Phone
- +1 2039376137
- Auditors
- EisnerAmper LLP
Latest News for NNVC
Upcoming Events for NNVC
Q3 2024 NanoViricides Inc Earnings Release
Q4 2024 NanoViricides Inc Earnings Release
Similar to NNVC
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
FAQ
As of Today at 19:15 UTC, shares in NanoViricides are trading at $1.10. This share price information is delayed by 15 minutes.
Shares in NanoViricides last closed at $1.10 and the price had moved by -17.91% over the past 365 days. In terms of relative price strength the NanoViricides share price has underperformed the S&P500 Index by -31.69% over the past year.
The overall consensus recommendation for NanoViricides is Buy. You can view the full broker recommendation list by unlocking its StockReport.
NanoViricides does not currently pay a dividend.
NanoViricides does not currently pay a dividend.
NanoViricides does not currently pay a dividend.
To buy shares in NanoViricides you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.10, shares in NanoViricides had a market capitalisation of $12.96m.
Here are the trading details for NanoViricides:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: NNVC
Based on an overall assessment of its quality, value and momentum NanoViricides is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in NanoViricides is $6.50. That is 490.91% above the last closing price of $1.10.
Analysts covering NanoViricides currently have a consensus Earnings Per Share (EPS) forecast of -$0.73 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NanoViricides. Over the past six months, its share price has underperformed the S&P500 Index by -18.79%.
As of the last closing price of $1.10, shares in NanoViricides were trading -11.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The NanoViricides PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
NanoViricides' management team is headed by:
- Anil Diwan - CHM
- Meeta Vyas - CFO
- Stanley Glick - IND
- Makarand Jawadekar - IND
- Theodore Rokita - IND
- Brian Zucker - IND